Cargando…

Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections

Amphotericin B (AmpB) is a polyene macrolide antibiotic used in the treatment of blood-borne parasitic and fungal infections. However, its use, particularly in the developing world, has been limited by dose-dependent kidney toxicity, other systemic-related toxicity issues following injection, the in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasan, Ellen, Mandava, Tavonga, Crespo-Moran, Pablo, Nagy, Adrienne, Wasan, Kishor M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697626/ https://www.ncbi.nlm.nih.gov/pubmed/36365135 http://dx.doi.org/10.3390/pharmaceutics14112316

Ejemplares similares

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?
por: Cuddihy, Grace, et al.
Publicado: (2019)

Efficacy of an oral and tropically stable lipid-based formulation of Amphotericin B (iCo-010) in an experimental mouse model of systemic candidiasis
por: Ibrahim, Fady, et al.
Publicado: (2013)

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model
por: Sivak, Olena, et al.
Publicado: (2011)

A Novel Tropically Stable Oral Amphotericin B Formulation (iCo-010) Exhibits Efficacy against Visceral Leishmaniasis in a Murine Model
por: Wasan, Ellen K., et al.
Publicado: (2010)

In vitro cytotoxicity of two novel oral formulations of Amphotericin B (iCo-009 and iCo-010) against Candida albicans, human monocytic and kidney cell lines
por: Leon, Carlos G, et al.
Publicado: (2011)

Design of amphotericin B oral formulation for antifungal therapy
por: Liu, Min, et al.
Publicado: (2017)

Analytical Strategies to Analyze the Oxidation Products of Phytosterols, and Formulation-Based Approaches to Reduce Their Generation
por: Gachumi, George, et al.
Publicado: (2021)

Phase I EnACT Trial of the Safety and Tolerability of a Novel Oral Formulation of Amphotericin B
por: Skipper, Caleb P., et al.
Publicado: (2020)

Encochleated Amphotericin B: Is the Oral Availability of Amphotericin B Finally Reached?
por: Aigner, Maria, et al.
Publicado: (2020)

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery
por: Mohammed, Munawar A., et al.
Publicado: (2017)

Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes
por: Ramos, Guilherme S., et al.
Publicado: (2022)

Effects of climate change on soil health resulting in an increased global spread of neglected tropical diseases
por: Wasan, John Paul M., et al.
Publicado: (2023)

Amphotericin B Formulations and Other Drugs for Visceral Leishmaniasis
por: Berman, Jonathan
Publicado: (2015)

Repurposing Amphotericin B and Its Liposomal Formulation for the Treatment of Human Mpox
por: Peruzzu, Daniela, et al.
Publicado: (2023)

Combination liposomal amphotericin B, posaconazole and oral amphotericin B for treatment of gastrointestinal Mucorales in an immunocompromised patient
por: Anderson, Anthony, et al.
Publicado: (2017)

Nephrotoxicity of three formulations of amphotericin B: trial sequential analysis
por: Caputo, Rosaria, et al.
Publicado: (2020)

Liposomal and Deoxycholate Amphotericin B Formulations: Effectiveness against Biofilm Infections of Candida spp.
por: Rodrigues, Célia F., et al.
Publicado: (2017)

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis
por: Jaafari, Mahmoud Reza, et al.
Publicado: (2019)

Liposomal Amphotericin B for Treatment of Leishmaniasis: From the Identification of Critical Physicochemical Attributes to the Design of Effective Topical and Oral Formulations
por: Frézard, Frédéric, et al.
Publicado: (2022)

Hesperidin-, Curcumin-, and Amphotericin B- Based Nano-Formulations as Potential Antibacterials
por: Akbar, Noor, et al.
Publicado: (2022)

Drug Delivery Technology Development in Canada
por: Wasan, Kishor M., et al.
Publicado: (2019)

Inhibition of Scavenger Receptor Class B Type 1 (SR-B1) Expression and Activity as a Potential Novel Target to Disrupt Cholesterol Availability in Castration-Resistant Prostate Cancer
por: Pandey, Mitali, et al.
Publicado: (2021)

Development and Characterization of Liposomal Formulations Containing Phytosterols Extracted from Canola Oil Deodorizer Distillate along with Tocopherols as Food Additives
por: Poudel, Asmita, et al.
Publicado: (2019)

Pharmacokinetics and Drug Metabolism in Canada: The Current Landscape—A Summary of This Indispensable Special Issue
por: Davies, Neal M., et al.
Publicado: (2018)

The effect of two novel cholesterol-lowering agents, disodium ascorbyl phytostanol phosphate (DAPP) and nanostructured aluminosilicate (NSAS) on the expression and activity of P-glycoprotein within Caco-2 cells
por: Sachs-Barrable, Kristina, et al.
Publicado: (2014)

Amphotericin B lipid formulations and target-site penetration into human body fluids
por: Weiler, Stefan, et al.
Publicado: (2008)

Confusion between Two Amphotericin B Formulations Leading to a Paediatric Rehospitalisation
por: Fleury, Mapi, et al.
Publicado: (2016)

Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate
por: Chandrasekar, PH
Publicado: (2008)

Formulation and characterisation of a self‐nanoemulsifying drug delivery system of amphotericin B for the treatment of leishmaniasis
por: Khan, Momin, et al.
Publicado: (2019)

Use of a Long-Acting Opioid Microsphere Formulation to Overcome Difficulties in Swallowing Pain Medication
por: Anderson, Nathan, et al.
Publicado: (2020)

LB1580. Efficacy Assessment of MAT2203 Encochleated Oral Formulation of Amphotericin B, in the Neutropenic Mouse Model of Pulmonary Mucormycosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2022)

An Amphotericin B Derivative Equally Potent to Amphotericin B and with Increased Safety
por: Antillón, Armando, et al.
Publicado: (2016)

Permeability Characteristics of a New Antifungal Topical Amphotericin B Formulation with γ-Cyclodextrins
por: López-Castillo, Carmen, et al.
Publicado: (2018)

Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection
por: Yang, Zhiwen, et al.
Publicado: (2014)

Copolymeric Micelles Overcome the Oral Delivery Challenges of Amphotericin B
por: Nimtrakul, Pataranapa, et al.
Publicado: (2020)

Untargeted metabolomics to understand the basis of phenotypic differences in amphotericin B-resistant Leishmania parasites
por: Pountain, Andrew W., et al.
Publicado: (2019)

Amphotericin-B in Dermatology
por: Agarwal, Akash, et al.
Publicado: (2022)

Amphotericin-B/amphotericin-B-liposomal: Lack of efficacy: 2 case reports
Publicado: (2022)

A Novel Cryptococcal Meningitis Therapy: The Combination of Amphotericin B and Posaconazole Promotes the Distribution of Amphotericin B in the Brain Tissue
por: Yang, Ming, et al.
Publicado: (2020)

Amphotericin B Loaded Polymeric Nanoparticles for Treatment of Leishmania Infections
por: Saqib, Mudassara, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8890k221otrvl0640vqd5koqg6